Chronic urticaria is a persistent skin condition characterized by recurrent wheals (hives) and/or angioedema lasting more than six weeks, significantly impacting quality of life and often requiring long-term management. Limited access to costly treatments like omalizumab poses challenges in low-income countries with high healthcare expenses and limited insurance coverage, prompting research into cost-effective dosages for effective management. This study aims to find the most cost-effective dosage for treating chronic urticaria in countries with healthcare affordability challenges. PubMed, MEDLINE, and Web of Science databases were searched for randomized controlled trials (RCTs) from January 1, 2010, to October 29, 2023. Studies assessing Omalizumab's efficacy in chronic spontaneous urticaria (CSU) patients unresponsive to antihistamines were included. Network meta-analyses (NMAs) were conducted using the "multinma" package in R, employing Bayesian random-effects models to synthesize data from multiple studies. Each outcome underwent separate analysis, with effect sizes illustrated via forest plots generated using Plotly in R. Individual studies' risk of bias was assessed using the Cochrane Risk of Bias Tool 2, and effect estimate certainty was rated via the GRADE approach. Consistency assumption was evaluated using the unrelated mean effects (UME) model, focusing on each data point's contribution to model fit. Present study showed that the 300 mg dose outperformed others and placebo in reducing urticaria activity score over 7 days (UAS7), weekly itch severity score (WWS), and weekly number of hives score (WIS). Response rates were notably higher with 300 mg, indicating its superiority in achieving treatment response. Given the significantly greater effect sizes of 150 mg and 300 mg over 75 mg and placebo, low doses aren't recommended for antihistamine-resistant cases. Initiating treatment with either a 300 mg dose for six months or starting with 150 mg and adjusting upwards as necessary is recommended, aligning with economic considerations until optimal dosages are established.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00403-024-03629-2DOI Listing

Publication Analysis

Top Keywords

chronic urticaria
12
risk bias
8
300 mg dose
8
urticaria
5
cost-effective omalizumab
4
omalizumab dosage
4
chronic
4
dosage chronic
4
urticaria systematic
4
systematic review
4

Similar Publications

Introduction: Chronic urticaria (CU) is not traditionally classified as an allergic disease, but emerging evidence suggests a link to atopy. The quintessential marker of atopy is IgE sensitization, there is scarce information on the IgE sensitization characteristics of CU.

Methods: To investigate IgE sensitization characteristics in CU, and compare them with classic allergic diseases.

View Article and Find Full Text PDF

Background: Chronic spontaneous urticaria (CSU) is an unpredictable inflammatory skin condition with substantial clinical burden that affects 0.23-0.78% of the United States population.

View Article and Find Full Text PDF

Patients' collaboration with healthcare providers, along with their individual dedication to follow medical recommendations, is a crucial component of effective therapy in chronic diseases. If a patient fails to fill their prescription, administers the medication improperly in terms of method and/or dosage, misses follow-up visits, or discontinues the treatment for any reason, these lapses can adversely affect disease management, impairing the effectiveness of symptom relief and prevention of progression and complications. A comparable situation pertains to allergic diseases, which require long-term and consistent treatment to achieve symptom alleviation and control.

View Article and Find Full Text PDF

Chronic idiopathic urticaria (CIU) is difficult for patients and healthcare professionals to manage owing to its chronic and unpredictable nature. While the exact cause of CIU is unknown, it is suggested that food allergies may contribute to the development of symptoms. To determine the prevalence of food allergy in patients diagnosed with CIU.

View Article and Find Full Text PDF

Mortality in adult patients with chronic spontaneous urticaria: A real world cohort study.

J Allergy Clin Immunol

December 2024

Institute of Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany.

Background: Chronic spontaneous urticaria (CSU), a common and debilitating disease, is widely held not to be life-limiting, but the mortality of CSU has not been investigated.

Objective: To assess all-cause mortality in CSU patients, risk for comorbidities that are leading causes of death and impact of guideline-recommended urticaria treatments on mortality rates.

Methods: This is a retrospective population-based cohort study of electronic health records of 272,190 adult CSU patients and 12,728,913 non-urticaria controls from the US Collaborative TriNetx Analytics Network.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!